Intravitreal ranibizumab for AMD : the individual rhythm of OCT guided retreatment intervals

Détails

ID Serval
serval:BIB_DADF575D1E1C
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Titre
Intravitreal ranibizumab for AMD : the individual rhythm of OCT guided retreatment intervals
Titre de la conférence
V. International Symposium of the German Ophthalmological Society (DOG), Baden-Baden September 8-10
Auteur(s)
Mantel I., Ambresin A., Deli A.
Organisation
German Society of Ophthalmology
Adresse
Baden-Baden
Statut éditorial
Publié
Date de publication
2011
Pages
Abstract 64P
Langue
anglais
Résumé
Purpose: We intended to determine whether the need for retreatmentwith intravitreal ranibizumab follows an individual rhythm in patientswith exudative AMD. Setting: Prospective mono-centre cohort study.Methods: Prospective study. 48 patients with exudative AMD. 3 loadingdoses of ranibizumab, followed by a 12 months PRN regimen guided byearly exudative signs on SD-OCT. An intensified follow-up allowed todetect recurrences early.Results:Mean VA improved by 6.4 letters at month 3 and by 13.1 letters atmonth 12, with a mean of 8.0 injections (range 0-12) during the maintenancephase. The intra-individual variance of the intervals was relativelysmall and ranged within 20% of themean interval in 91% of patients.Thefirst interval was within 1 week of the mean interval in 84% of patients.The retreatment criteria were stable in 89% of patients.Conclusion: The relative stability of the intra-individual intervalsmay allowsimplifying the care for AMDpatients.Theremay be a predictive role for thefirst interval after the loading phase. The functional results of this PRNregimenwith early retreatmentwere excellent. Financial disclosure:None.
Création de la notice
12/03/2012 12:22
Dernière modification de la notice
19/03/2018 11:57
Données d'usage